Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 6/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.39 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090031 | 0.82 | NPC1 (0.50) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL345703 | 0.74 | MAPT (0.47) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL11198759 | 0.73 | PDE3B (0.36) | — | |
| SCHEMBL4023131 | 0.73 | AHR (0.37) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL1235044 | 0.71 | AHR (0.70) | AHRPDK2GSK3BCDK5CDK5R1 | |
| SCHEMBL6379887 | 0.71 | AHR (0.70) | AHRPDK2GSK3BCDK5CDK5R1 | |
| SCHEMBL29510715 | 0.71 | AHR (0.70) | AHRPDK2GSK3BCDK5CDK5R1 | |
| SCHEMBL1450805 | 0.69 | ALDH1A1 (0.33) | ALDH1A1MAPTBRD4CREBBPEP300 | |
| SCHEMBL1340168 | 0.68 | MMP12 (0.40) | AHRPDK2GSK3BCDK5CDK5R1 | |
| SCHEMBL970504 | 0.68 | AHR (0.48) | AHRPDK2GSK3BCDK5CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | claimed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | claimed |
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | Suzhou Puhe BioPharma Co., Ltd. (CN) | 2023-01-12 | — | — | US | claimed |
| CN-107072205-B | SMYD inhibitors | EPIZYME股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-114502165-A | SHP2 inhibitor and application thereof | 苏州浦合医药科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20210276952-A1 | NOVEL COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-09-09 | — | — | US | claimed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| EP-3810131-A1 | NOVEL COMPOUNDS | UCL Business Ltd (GB) | 2021-04-28 | — | — | EP | claimed |
| WO-2021061515-A1 | SHP2 INHIBITORS AND USES THEREOF | SYNBLIA THERAPEUTICS, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| EP-2351737-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | claimed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | claimed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | claimed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | claimed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | claimed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | claimed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010886-A1 | SHP2 INHIBITORS AND USES THEREOF | PTPN1, PTPN7, PTPN18 | AHR 1973/4885PDK2 1310/4885GSK3B 675/4885 |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | IDO1, RB1, AHR | AHR 3/4885PDK2 2085/4885GSK3B 679/4885 |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | GPX4, GPX1, ACAT1 | AHR 352/4885PDK2 301/4885GSK3B 2455/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | AHR 3844/4885PDK2 1240/4885GSK3B 453/4885 |
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | AHR 346/4885PDK2 3897/4885GSK3B 3602/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | AHR 332/4885PDK2 3912/4885GSK3B 3552/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | AHR 2472/4885PDK2 1991/4885GSK3B 4088/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | AHR 1593/4885PDK2 2166/4885GSK3B 3241/4885 |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | AHR 1029/4885PDK2 1161/4885GSK3B 716/4885 |
| US-20210276952-A1 | NOVEL COMPOUNDS | SERPINC1, SERPINA2, SERPINA3 | AHR 3072/4885PDK2 3194/4885GSK3B 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.